pasiniazid (Shanghai Pulmonary Hospital)

Pasiniazid (isoniazid aminosalicylate) is a chemical salt combining two potent anti-tuberculosis agents: isoniazid and para-aminosalicylic acid (PAS). It is primarily utilized in the treatment of pulmonary tuberculosis, particularly in retreatment regimens where drug resistance or treatment failure has occurred. Isoniazid, a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG, inhibits the enoyl-acyl carrier protein reductase (InhA), which is essential for the synthesis of mycolic acids in the mycobacterial cell wall. Para-aminosalicylic acid acts as an antimetabolite that competitively inhibits dihydropteroate synthase (DHPS), thereby disrupting the biosynthesis of folic acid. The salt formulation is designed to provide the synergistic therapeutic effects of both components while potentially improving chemical stability and patient compliance compared to separate administration. It has been the subject of clinical research in China, notably in Phase 4 trials led by Shanghai Pulmonary Hospital evaluating super-short course regimens for retreatment tuberculosis.

Brand names

PasiazidLipaihuiji

Other names

isoniazid aminosalicylateisoniazid 4-aminosalicylateisoniazid4-aminosalicylateisoniazid-4-aminosalicylatepasiniazideisoniazid p-aminosalicylate